Switch theme
Sign up to access all valuation multiples
Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of inventive products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategies.
2016
122
LTM Revenue $115M
LTM EBITDA $14.2M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kuros Biosciences has a last 12-month revenue (LTM) of $115M and a last 12-month EBITDA of $14.2M.
In the most recent fiscal year, Kuros Biosciences achieved revenue of $90.7M and an EBITDA of -$0.7M.
Kuros Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kuros Biosciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $115M | XXX | $90.7M | XXX | XXX | XXX |
| Gross Profit | $98.6M | XXX | $74.5M | XXX | XXX | XXX |
| Gross Margin | 86% | XXX | 82% | XXX | XXX | XXX |
| EBITDA | $14.2M | XXX | -$0.7M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | -1% | XXX | XXX | XXX |
| EBIT | $1.6M | XXX | -$6.0M | XXX | XXX | XXX |
| EBIT Margin | 1% | XXX | -7% | XXX | XXX | XXX |
| Net Profit | $1.1M | XXX | -$4.5M | XXX | XXX | XXX |
| Net Margin | 1% | XXX | -5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Kuros Biosciences's stock price is CHF 26 (or $32).
Kuros Biosciences has current market cap of CHF 997M (or $1.2B), and EV of CHF 981M (or $1.2B).
See Kuros Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $1.2B | XXX | XXX | XXX | XXX | $0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Kuros Biosciences has market cap of $1.2B and EV of $1.2B.
Kuros Biosciences's trades at 13.0x EV/Revenue multiple, and -1749.0x EV/EBITDA.
Equity research analysts estimate Kuros Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kuros Biosciences has a P/E ratio of 1044.9x.
See valuation multiples for Kuros Biosciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 10.3x | XXX | 13.0x | XXX | XXX | XXX |
| EV/EBITDA | 83.1x | XXX | -1749.0x | XXX | XXX | XXX |
| EV/EBIT | 715.7x | XXX | -196.4x | XXX | XXX | XXX |
| EV/Gross Profit | 11.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 1044.9x | XXX | -268.3x | XXX | XXX | XXX |
| EV/FCF | 756.7x | XXX | 483.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKuros Biosciences's last 12 month revenue growth is 49%
Kuros Biosciences's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.7M for the same period.
Kuros Biosciences's rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Kuros Biosciences's rule of X is 135% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Kuros Biosciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 49% | XXX | 49% | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | -1% | XXX | XXX | XXX |
| EBITDA Growth | 75% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 18% | XXX | 48% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 135% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 48% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 89% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kuros Biosciences acquired XXX companies to date.
Last acquisition by Kuros Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Kuros Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Kuros Biosciences founded? | Kuros Biosciences was founded in 2016. |
| Where is Kuros Biosciences headquartered? | Kuros Biosciences is headquartered in Switzerland. |
| How many employees does Kuros Biosciences have? | As of today, Kuros Biosciences has 122 employees. |
| Is Kuros Biosciences publicy listed? | Yes, Kuros Biosciences is a public company listed on SWX. |
| What is the stock symbol of Kuros Biosciences? | Kuros Biosciences trades under KURN ticker. |
| When did Kuros Biosciences go public? | Kuros Biosciences went public in 2002. |
| Who are competitors of Kuros Biosciences? | Similar companies to Kuros Biosciences include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Kuros Biosciences? | Kuros Biosciences's current market cap is $1.2B |
| What is the current revenue of Kuros Biosciences? | Kuros Biosciences's last 12 months revenue is $115M. |
| What is the current revenue growth of Kuros Biosciences? | Kuros Biosciences revenue growth (NTM/LTM) is 49%. |
| What is the current EV/Revenue multiple of Kuros Biosciences? | Current revenue multiple of Kuros Biosciences is 10.3x. |
| Is Kuros Biosciences profitable? | Yes, Kuros Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Kuros Biosciences? | Kuros Biosciences's last 12 months EBITDA is $14.2M. |
| What is Kuros Biosciences's EBITDA margin? | Kuros Biosciences's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of Kuros Biosciences? | Current EBITDA multiple of Kuros Biosciences is 83.1x. |
| What is the current FCF of Kuros Biosciences? | Kuros Biosciences's last 12 months FCF is $1.6M. |
| What is Kuros Biosciences's FCF margin? | Kuros Biosciences's last 12 months FCF margin is 1%. |
| What is the current EV/FCF multiple of Kuros Biosciences? | Current FCF multiple of Kuros Biosciences is 756.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
